Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators

BACKGROUND: Immune checkpoint blocker (ICB) has shown significant clinical activity in melanoma. However, there are no clinically approved biomarkers to aid patient selection. We aimed to identify patients with advanced or metastatic melanoma who are likely to benefit from ICB monotherapy using easi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Byun, Hwa Kyung, Chang, Jee Suk, Jung, Minkyu, Koom, Woong Sub, Chung, Kee Yang, Oh, Byung Ho, Roh, Mi Ryung, Kim, Kyung Hwan, Lee, Choong-Kun, Shin, Sang Joon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8190329/
https://ncbi.nlm.nih.gov/pubmed/34123816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.659754
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller